in foods is through the Maillard reaction during food processing at temperatures higher than >120ºC 27 (i.e. frying or baking) 2, 3 , but acrylamide has also been observed in foods treated at lower 28 temperatures (e.g., low moisture drying) 4 . In the European Prospective Investigation into Cancer and 29 Nutrition (EPIC), the major food contributors to dietary acrylamide intake (based on a 24-h dietary 30 recall; 24hDR) were bread, crisp bread, rusks, coffee, and potatoes
5
. 31
In the human body, acrylamide is conjugated with reduced glutathione for elimination, or is 32 metabolized to glycidamide through the Cyp2e1 enzyme system. In animal studies, after acrylamide 33 administration, both hormone-and non-hormone-related tumors have been observed 1 . Glycidamide 34 is believed to have mutagenic and genotoxic effects in animals, whereas acrylamide is thought to be 35 neurotoxic both in animals and in humans 3, 6 , and may also disrupt hormonal homeostasis 7, 8 . 36
Acrylamide and its metabolite glycidamide can form adducts with hemoglobin (HbAA and HbGA, 37 respectively), which are stable over the lifespan of erythrocytes (approximately 120 days), and thus, 38 have been extensively used as biomarkers of human internal exposure 3, 9 . The mean hemoglobin 39 adduct levels in smokers are at least three to four times higher than non-smokers 10 , and cigarette 40 smoke is considered as one of the major sources of acrylamide exposure. Thus, to assess the impact 41 of dietary acrylamide on health, non-smokers are considered a more suitable population than 42 smokers. 43
Cancer of the corpus uteri is the fourth most common incident cancer in European and North 44
American women. The most common type of corpus uteri cancer is endometrial cancer (EC). The 5-45 year survival rate of EC is high, ranging from 65 to 85% 11 . EC has been classified into type-I and type-46 dependent tumor. In contrast, type-II EC is usually serous carcinoma, is thought to be estrogen-48 independent, usually diagnosed in elderly women, and generally has an unfavorable prognosis 12, 13 . 49
Epidemiological data suggest that obesity, diabetes, low physical activity, long-term exposure to 50 estrogens, and a history of polycystic ovary syndrome are risk factors for developing EC, and type-I 51 EC in particular 14 . Combined oral contraceptive (OC) use, and tobacco smoking are consistently 52 associated with lower risk of EC
14
. Further, a recent EPIC study observed an inverse association 53 between coffee consumption and EC risk 15 . 54
To date, four prospective epidemiologic studies, including one from EPIC, have evaluated the 55 association between dietary intake of acrylamide (assessed through dietary questionnaires; DQs) 56 and EC risk [16] [17] [18] [19] . Two subsequent meta-analyses concluded that dietary acrylamide intake was not 57 associated with overall EC risk, but increased risk was observed with higher acrylamide intakes in 58 women who were never smokers at baseline 20, 21 . To our knowledge, this is the first nested-case 59 control study within a prospective cohort study designed to assess the relation between circulating, 60 red blood cell hemoglobin adducts of acrylamide and glycidamide and overall and type-I EC risk. 61
Material and Methods

62
The EPIC study comprises 10 European countries and 23 research centers with the aim to evaluate 63 the association between nutrition and lifestyle factors, cancer and other chronic diseases 22 . The 64 current study includes participants from 8 of the 10 EPIC countries: Denmark, Norway, and one 65 center from Sweden (Malmö) did not participate. For each EPIC center, subjects were followed until 66 cancer diagnosis (except non-melanoma skin cancer), emigration, death, or end of follow-up, which 67 varied from December 2005 to June 2010). 68
The EPIC methodology has been published elsewhere 22 . Recruitment began between 1992-1998, and 69 participants reported information on dietary habits (referring to the twelve months before 70 recruitment) assessed through country-specific, validated dietary questionnaires (DQs). Additionally, 71 information on tobacco smoking, education, physical activity, anthropometric measures and 72 reproductive factors was also obtained at recruitment. Blood samples were collected at recruitment 73 for approximately 80% of the EPIC cohort (385,747 of over 500,000 participants). Samples that were 74 stored at the IARC bio-bank were kept in liquid nitrogen (-196 o C); whereas blood samples from 75
Umeå were stored at local repositories in freezers (-80 o C). The selection of the study population for the present nested case-control study was based on the 89 algorithm that has been previously published by Cust et al. and Peeters et al. 23 : for each EC case two 90 corresponding controls were randomly selected at the date of diagnosis (subjects free of cancer, 91 with the exception of non-melanoma skin cancer). Cases and controls were matched by study 92 center, menopausal status, age at recruitment (±6 months), date at blood collection (± 1 month), 93 time of the day of blood draw (±1 hour), and fasting status (<3, 3-6, >6 hours). Individual matching 94 was broken in the present study (one control per case) because we only included women who were 95 non-smokers, defined as women who reported never smoking or who quit smoking ≥5 years before 96 recruitment, and who were postmenopausal at blood draw, defined as women who reported not 97 having menses ≥1 year before recruitment. 98 A total of 771 subjects (385 EC cases and 386 controls) were included in the study. Of these, three 99 had to be excluded due to the lack of information on HbAA (n=2 cases) or HbGA (n=1 control), 100 leaving 383 EC cases and 385 controls included in the final analyses. Only one observation had an 101
HbGA value below the LOD; thus, we assigned half of the corresponding value of the LOD (2 pmol/g 102 Hb In order to improve normality of the distributions, all biomarker variables were log-transformed 107 (log2) and were evaluated as: log2HbAA, log2HbGA, sum of total adducts [log2(HbAA+HbGA)], and 108
HbGA/HbAA ratio. Additionally, these four continuous variables were categorized into quintiles 109 based on the distribution in the control group. Unconditional logistic regression models were used to 110 estimate odds ratios (ORs) and 95% confidence intervals (CI). Analyses were also performed 111 separately for type-I EC tumors. 112
All statistical models were adjusted for matching variables (age at recruitment (years), country, date 113 of blood draw, time of day of the blood draw, and fasting status), and other covariates such as ever 114 use of OC (never, ever), ever use of hormone replacement therapy (never, ever; HRT), parity 115 (nulliparous, 1, 2, ≥3, parous but with missing number of full-term pregnancies), age at menopause 116 (years), body mass index (kg/m 2 ; BMI), and alcohol intake (non-drinkers, drinkers of 0-6, >6-12, >12-117 24, and >24 g/day). The following variables were evaluated as potential confounders but were not 118 included in final models because they did not change the risk estimates by >10%: dietary variables 119 (such as coffee, potatoes, biscuits, crackers, and cakes), history of diabetes (yes, no), age atmenarche (<12, 12, 13, 14, ≥15 years), height (cm), weight (kg), hip circumference (cm), waist 121 circumference (cm), physical activity using the Cambridge index 24 , and education level (none, 122 primary, technical/professional, secondary, and higher education). 123
Effect-measure modification was evaluated for established risk factors, and for factors considered to 124 affect the activity of Cyp2e1: BMI (<25 vs ≥25 kg/m 2 ), HRT use (never vs ever users), OC (never vs 125 ever users), and alcohol intake (never vs ever drinkers ) 5 using a likelihood ratio test (LRT) based on 126 categorical biomarker variables. For each biomarker quartile, the median was estimated, and was 127 included in a score test to evaluate dose-response trends. 128
The reproducibility of the hemoglobin adducts measurements was assessed using 43 (5%) duplicate 129 blood samples revealing intraclass correlation coefficients of 0.92 for HbAA and 0.95 for HbGA. All 130 statistical tests were two-sided and statistical significance was set at p <0.05. All analyses were 131 performed using SAS v. 9.1 (Cary, North Carolina, USA). 132
Results
133
A large number of cases and controls were from Italy and the United Kingdom, and the major 134 proportion of type-I EC cases were from Germany and The Netherlands ( Table 1 ). The median 135 interval between the dates at blood collection and diagnosis was 6.2 years. Among cases, the 136 median (25 th -75 th percentile) HbAA and HbGA adducts levels were 39.9 (31.4-52.4) and 34.1 (25.7-137 44.6) pmol/g Hb, respectively; and in controls 39.4 (32.1-51.1) and 33.3 (24.6-43.8) pmol/g Hb, 138
respectively. As compared with controls, cases were slightly younger, had a slightly higher 139 proportion of heavy drinking (6.5% vs 5.5%), tended to use less OCs (32.4% vs 36.4%) and more HRT 140 (Table 2) . We also restricted the 145 analyses to known type-I EC cases and no statistically significant associations were observed (Table  146 2). Associations between biomarkers of exposure and overall or type-I EC risk were also assessed 147 using tertiles, quartiles, and deciles (based on the exposure distribution in the control group), and no 148 significant variations in risk were observed across categories (data not shown). 149
Subgroup analyses for overall EC were stratified by BMI (<25, ≥25 kg/m 2 ), alcohol intake (never 150 drinkers, ever drinkers), HRT use (never HRT users, ever HRT users; data not shown), and OC use 151 (never OC users, ever OC users). No evidence for effect measure modification was observed in any of 152 the subgroups evaluated (all LRT P-values >0.05) ( Table 3 ). Due to the small sample size, stratified 153 analyses for type-I EC were conducted using tertiles, and results indicated no heterogeneity (data 154 not shown). 155
Discussion
156
The present nested case-control study within the EPIC cohort is the first epidemiologic study to 157 evaluate the association between biomarkers of acrylamide exposure and endometrial cancer risk. 158
We did not observe any evidence to support the hypothesis that levels of biomarkers of acrylamide 159 and glycidamide exposure measured as hemoglobin adducts (HbAA, HbGA, sum of total adducts, and 160
HbGA/HbAA ratio) were associated with the risk of developing overall EC or type-I EC in non-smoking 161 postmenopausal women. Furthermore, there was no evidence for effect measure modification by 162 BMI, alcohol intake, HRT use, or OC use though there was relatively limited power to assess 163 heterogeneity among subgroups. 164
The present study was based on a subgroup of non-smoking postmenopausal women in the EPIC 165 cohort to address two major concerns. First, tobacco smoking is considered one of the major sources 166 of acrylamide exposure, and it is recognized that smokers have higher levels of acrylamide 167 biomarkers 10 ; second, hormonal homeostasis may be disrupted by acrylamide 7, 8 , thus, the analyses 168 were performed in non-smoking postmenopausal women only. 169
The lack of association between biomarkers of acrylamide exposure and overall and type-I EC risk is 170 in agreement with results we previously reported in the EPIC sub-cohort of women, where hazard 171 ratios were estimated for the association between dietary acrylamide intake (assessed through DQs ) 172 and overall EC (n=1382) or type-I EC risk (n=627); nevertheless, in the full cohort analysis, positive 173 associations were reported between acrylamide intake and type-I EC risk in women who were never 174 smokers and non-users of OCs
19
. In the present study, using circulating biomarkers of acrylamide 175 exposure, we did not replicate these results possibly due to the small sample size with tumor 176 histology information (n=171 type-I EC cases). Additionally, the null results based on Two recent meta-analyses concluded that higher consumption of dietary acrylamide was 184 significantly associated with overall EC risk in never smoking women; but not in all women combined 185 20, 21 . In the present study of acrylamide and glycidamide biomarkers and EC risk in non-smoking 186 postmenopausal women, we did not observe any evidence for associations with overall or type-I EC 187
risk. 188
The main strengths of the present nested case-control study are its study design, with the intention 189 to prevent confounding from tobacco smoking and hormonal fluctuations, and the use of 190 prospective information on the main risk factors for EC. The minimum detectable ORs at 80% power 191 in our study were 1.22 and 1.60 for the continuous and categorical variables, respectively. missing values (>50%). In a subset of the present study with available data, no statistically significant 209 differences in Hb-adducts levels were observed between controls who reported not being exposed 210 to SHS (n=80) and controls who were exposed to SHS (n=53) (data not presented). Moreover, two 211 additional studies reported null or negligible effects of SHS on biomarkers of acrylamide exposure 212 27, 28 . (d) Despite having information on tumor histology for 97% of the EC cases (of which 46% were 213 classified as type-I), we were not able to analyze type-II EC due to the small sample size (n=14). 214
In conclusion, this study does not provide evidence of an association between levels of hemoglobin 215 adducts of acrylamide and glycidamide and risks of overall EC and type-I EC. 216 Tables Table 1. a Median and quartile range (25th -75th percentile).
b number (n) and percent (%).
2 All models are adjusted for age at recruitment, country, fasting status, date at blood collection, time of the day of blood collection, OC use, HRT use, alcohol intake, parity, age at menopause, and BMI. a Adjusted for age at recruitment, country, fasting status, date at blood collection, OC use, HRT use, alcohol intake, parity, and age at menopause.
b Adjusted for age at recruitment, country, fasting status, date at blood collection, OC use, HRT use, parity, age at menopause, and BMI.
c Adjusted for age at recruitment, country, fasting status, date at blood collection, HRT use, alcohol intake, parity, age at menopause, and BMI.
d All LRT P-values for effect measure modification are based on the categorical exposure adduct variable.
